SB driver analysis: A sleeping beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors

Justin Y. Newberg, Michael A. Black, Nancy A. Jenkins, Neal G. Copeland, Karen M. Mann, Michael B. Mann

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Cancer driver prioritization for functional analysis of potential actionable therapeutic targets is a significant challenge. Meta-analyses of mutated genes across different human cancer types for driver prioritization has reaffirmed the role of major players in cancer, including KRAS, TP53 and EGFR, but has had limited success in prioritizing genes with non-recurrent mutations in specific cancer types. Sleeping Beauty (SB) insertional mutagenesis is a powerful experimental gene discovery framework to define driver genes in mouse models of human cancers. Meta-analyses of SB datasets across multiple tumor types is a potentially informative approach to prioritize drivers, and complements efforts in human cancers. Here, we report the development of SB Driver Analysis, an in-silico method for defining cancer driver genes that positively contribute to tumor initiation and progression from population-level SB insertion data sets. We demonstrate that SB Driver Analysis computationally prioritizes drivers and defines distinct driver classes from end-stage tumors that predict their putative functions during tumorigenesis. SB Driver Analysis greatly enhances our ability to analyze, interpret and prioritize drivers from SB cancer datasets and will continue to substantially increase our understanding of the genetic basis of cancer.

Original languageEnglish (US)
Article numbere94
JournalNucleic Acids Research
Volume46
Issue number16
DOIs
StatePublished - Sep 2018

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'SB driver analysis: A sleeping beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors'. Together they form a unique fingerprint.

Cite this